News

Sorrento Therapeutics rejects takeover offer.

Read time: 1 mins

Published:28th Jan 2020

Sorrento Therapeutics, Inc. announced that, after reviewing the latest acquisition proposal in consultation with its advisors, Sorrento’s Board of Directors (the “Board”) determined that the offer significantly undervalues Sorrento and is not in the best interest of the Company’s stockholders. Sorrento’s management continues to execute on the core drug development and to pursue multiple potential strategic alliances and transactions. Accordingly, the Board unanimously rejected the acquisition proposal.

Type: industry

Learning Zone Homepage

Advances in HS

The latest updates in HS from the 2024 European Hidradenitis Suppurativa Foundation Conference, 7–9 February in Lyon

Learning Zone

All Things Angioedema and Urticaria: Podcasts

In these podcasts, our hosts, Professor Marcus Maurer and Dr Thomas Buttgereit are joined by friends and colleagues to discuss all things related to angioedema and urticaria.

Learning Zone Homepage

Ulcerative colitis Learning Zone

Explore the role of biologics and targeted small molecules in UC management, and listen to expert insights on integrating them into practice.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

Kesimpta (ofatumumab) six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis

Novartis announced new long-term data from the ALITHIOS open-label extension study showing that up to five years, patients treated earlier and continuously with Kesimpta (ofatumumab) had fewer disability worsening events and low brain volume change versus those who started on teriflunomide and were later switched to Kesimpta

6 mins

Drug news

Positive phase III topline results from Study 501 evaluating lumateperone as adjunctive therapy in patients with major depressive disorder

Intra-Cellular Therapies, Inc. a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, announced positive topline results from Study 501 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD)

2 min

Drug news

FDA approval of Dovato (dolutegravir/lamivudine) for adolescents living with HIV

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, announced the FDA approved Dovato (dolutegravir/lamivudine) for the treatment of HIV-1 infection in adolescents 12 years of age and older and weighing at least 25 kg with no antiretroviral (ARV) treatment history or to replace the current ARV regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable ARV regimen with no history of treatment failure and no known substitutions associated with resistance to the individual components of Dovato

1 min

See all news